石四药集团(02005.HK)1月6日耗资446.94万港元回购150万股 石四药集团(02005.HK)：取得有关培哚普 利氨氯地平片(Ⅲ)(精氨酸培哚普利10mg、苯磺酸氨氯地平5mg)的药品生产注册批件 相关事件 格隆汇1月6日丨石四药集团(02005.HK)发布公告，2026年1月6日耗资446.94万港元回购150万股，回购 价格每股2.96-3港元。 ...

Major Events - Yunzhisheng (09678) secured a regional medical cooperation contract worth over 20 million [1] - Kelun-Biotech (06990) received breakthrough therapy designation from NMPA for TROP2 ADC drug in combination with pembrolizumab for treating PD-L1 positive locally advanced or metastatic non-small cell lung cancer [1] - InSilico Medicine (03696) entered into an 8.88 billion USD multi-year collaboration for anti-tumor drug development with Sihuiya [1] - Hutchison China MediTech (00013) is conducting a Phase III study on surufatinib combined with camrelizumab for first-line treatment of pancreatic ductal adenocarcinoma [1] - Ascletis Pharma-B (01672) announced FDA approval for IND of ASC30 in a 13-week Phase II study in diabetic patients [1] - Foryou Medical (01696) received quality standard inspection approval for its reauthorized injectable botulinum toxin from the Chinese National Medical Products Administration [1] - CanSino Biologics (06185) obtained clinical trial approval in China for its 24-valent pneumococcal polysaccharide conjugate vaccine [1] - Stone Group (02005) received drug production registration approval for perindopril and amlodipine tablets [1] - Sunny Optical Technology (02382) proposed to spin off its automotive optical business for independent listing on the Hong Kong Stock Exchange [1] - Dongyang Sunshine Pharmaceutical (06887) completed the first patient enrollment for HECN30227 in China [1] - Haitong International's subsidiary plans to sell 100% equity of Guohua Machinery for 342 million [1] - Yuexiu Property (00123) subsidiary intends to sell 73.74% actual equity in Hangzhou Yueyun [1] - CIMC Group (02039) subsidiary CIMC Shilianda plans to introduce strategic investors through capital increase and transfer of a small number of old shares [1] Operating Performance - Chifeng Jilong Gold Mining (06693) expects annual net profit attributable to shareholders to be approximately 3 billion to 3.2 billion, an increase of about 70% to 81% year-on-year [2] - Corning Hospital (02120) anticipates outpatient visits to reach approximately 720,200 in 2025, a year-on-year increase of 29% [2] - Seres (09927) reported total vehicle sales of 63,700 units in December, a year-on-year increase of 53.54% [2] - Xiehe New Energy (00182) reported an equity power generation of 790.32 GWh in December [2] - Country Garden (02007) reported contract sales amounting to approximately 2.69 billion attributable to shareholders in December [2]

培哚普利氨氯地平片(Ⅲ)是复方制剂，主要用于单药治疗不能充分控制高血压的成人患者，或作为替代 疗法用于在相同剂量水平的培哚普利和氨氯地平联合治疗下病情得以控制的原发性高血压。 智通财经APP讯，石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关培哚普利氨氯 地平片(Ⅲ)(精氨酸培哚普利10mg、苯磺酸氨氯地平5mg)的药品生产注册批件，属于化学药品第4类，视 同通过一致性评价。 ...

格隆汇1月5日丨石四药集团(02005.HK)公告，集团已取得中国国家药品监督管理局有关培哚普利氨氯地 平片(Ⅲ)(精氨酸培哚普利10mg、苯磺酸氨氯地平5mg)的药品生产注册批件，属于化学药品第4类，视同 通过一致性评价。 培哚普利氨氯地平片(Ⅲ)是复方制剂，主要用于单药治疗不能充分控制高血压的成人患者，或作为替代 疗法用于在相同剂量水平的培哚普利和氨氯地平联合治疗下病情得以控制的原发性高血压。 ...